EA010240B1 - 1α-ФТОР-25-ГИДРОКСИ-16,23Е-ДИЕН-26,27-БИСГОМО-20-ЭПИХОЛЕКАЛЬЦИФЕРОЛ И ЕГО ПРИМЕНЕНИЕ ДЛЯ ЛЕЧЕНИЯ - Google Patents

1α-ФТОР-25-ГИДРОКСИ-16,23Е-ДИЕН-26,27-БИСГОМО-20-ЭПИХОЛЕКАЛЬЦИФЕРОЛ И ЕГО ПРИМЕНЕНИЕ ДЛЯ ЛЕЧЕНИЯ Download PDF

Info

Publication number
EA010240B1
EA010240B1 EA200401100A EA200401100A EA010240B1 EA 010240 B1 EA010240 B1 EA 010240B1 EA 200401100 A EA200401100 A EA 200401100A EA 200401100 A EA200401100 A EA 200401100A EA 010240 B1 EA010240 B1 EA 010240B1
Authority
EA
Eurasian Patent Office
Prior art keywords
compound
treatment
fluoro
diene
bph
Prior art date
Application number
EA200401100A
Other languages
English (en)
Russian (ru)
Other versions
EA200401100A1 (ru
Inventor
Лучано Адорини
Энрико Колли
Original Assignee
Биокселл Спа
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB0322395A external-priority patent/GB0322395D0/en
Priority claimed from GB0325598A external-priority patent/GB2407499B/en
Priority claimed from GB0416876A external-priority patent/GB0416876D0/en
Application filed by Биокселл Спа filed Critical Биокселл Спа
Publication of EA200401100A1 publication Critical patent/EA200401100A1/ru
Publication of EA010240B1 publication Critical patent/EA010240B1/ru

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/59—Compounds containing 9, 10- seco- cyclopenta[a]hydrophenanthrene ring systems
    • A61K31/593—9,10-Secocholestane derivatives, e.g. cholecalciferol, i.e. vitamin D3
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/59—Compounds containing 9, 10- seco- cyclopenta[a]hydrophenanthrene ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/04—Drugs for disorders of the urinary system for urolithiasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/10—Drugs for disorders of the urinary system of the bladder
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/02—Nutrients, e.g. vitamins, minerals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Urology & Nephrology (AREA)
  • Epidemiology (AREA)
  • Nutrition Science (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
EA200401100A 2003-09-24 2004-09-23 1α-ФТОР-25-ГИДРОКСИ-16,23Е-ДИЕН-26,27-БИСГОМО-20-ЭПИХОЛЕКАЛЬЦИФЕРОЛ И ЕГО ПРИМЕНЕНИЕ ДЛЯ ЛЕЧЕНИЯ EA010240B1 (ru)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB0322395A GB0322395D0 (en) 2003-09-24 2003-09-24 Methods for treating bladder dysfunction and related compounds and compositions
GB0325598A GB2407499B (en) 2003-11-03 2003-11-03 Vitamin D3 analogue for use in the treatment of BPH
GB0416876A GB0416876D0 (en) 2004-07-29 2004-07-29 Compound and use in treatment

Publications (2)

Publication Number Publication Date
EA200401100A1 EA200401100A1 (ru) 2005-04-28
EA010240B1 true EA010240B1 (ru) 2008-06-30

Family

ID=34229055

Family Applications (1)

Application Number Title Priority Date Filing Date
EA200401100A EA010240B1 (ru) 2003-09-24 2004-09-23 1α-ФТОР-25-ГИДРОКСИ-16,23Е-ДИЕН-26,27-БИСГОМО-20-ЭПИХОЛЕКАЛЬЦИФЕРОЛ И ЕГО ПРИМЕНЕНИЕ ДЛЯ ЛЕЧЕНИЯ

Country Status (12)

Country Link
EP (1) EP1673096A1 (fr)
JP (2) JP2007506699A (fr)
CN (1) CN100488511C (fr)
BE (1) BE1016292A3 (fr)
BR (1) BRPI0404050A (fr)
CH (1) CH698144B1 (fr)
EA (1) EA010240B1 (fr)
FR (1) FR2859910B1 (fr)
HK (1) HK1085373A1 (fr)
NL (1) NL1027109C2 (fr)
NZ (1) NZ535531A (fr)
WO (1) WO2005027923A1 (fr)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006038611A1 (fr) * 2004-10-05 2006-04-13 Kissei Pharmaceutical Co., Ltd. Agent pour le traitement prophylactique ou thérapeutique des troubles de collecte de l'urine dans la vessie consécutifs à l'obstruction du canal urinaire inférieur
KR20070059152A (ko) * 2004-10-06 2007-06-11 깃세이 야쿠힌 고교 가부시키가이샤 전립선 비대증에 대한 수술요법으로의 이행 예방용 의약조성물
US20100009949A1 (en) * 2006-03-24 2010-01-14 Bioxell S.P.A. Novel method
US8221803B1 (en) 2007-06-25 2012-07-17 OncoNatural Solutions, Inc. Composition for prostate health
US20120164240A1 (en) 2010-12-22 2012-06-28 Audino David Lawrence Enriched a. blitoides compositions and uses thereof
US20170049834A1 (en) * 2015-08-18 2017-02-23 Golden Biotechnology Corporation Benign prostatic hyperplasia add-on therapy
FR3063906A1 (fr) * 2017-03-20 2018-09-21 Pierre Fabre Medicament Utilisation de l'oleoresine de copaifera dans les pathologies de la prostate

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0808833A2 (fr) * 1996-05-23 1997-11-26 F. Hoffmann-La Roche Ag Analogues de la vitamine D3
US5872113A (en) * 1997-05-16 1999-02-16 Syntex (U.S.A.) Inc. Fluorinated vitamin D3 analogs
US6030963A (en) * 1995-11-22 2000-02-29 Hoffmann-La Roche Inc. 16-ene-26,27-bishomo cholecalciferols
EP1048661A2 (fr) * 1999-04-26 2000-11-02 F. Hoffmann-La Roche Ag Procédé de préparation d'un agent anti-ostéoporotique
US6479538B1 (en) * 1997-05-16 2002-11-12 Women And Infants Hospital Cyclic ether vitamin D3 compounds, 1α(OH)3-EPI-vitamin D3 compounds and uses thereof

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5763429A (en) * 1993-09-10 1998-06-09 Bone Care International, Inc. Method of treating prostatic diseases using active vitamin D analogues
WO2003034961A1 (fr) * 2001-10-23 2003-05-01 Euro-Celtique, S.A. Procedes et dispositif transdermique de terazosine
IL162213A0 (en) * 2001-12-03 2005-11-20 Novacea Inc Pharmaceutical compositions containing active vitamin d compounds

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6030963A (en) * 1995-11-22 2000-02-29 Hoffmann-La Roche Inc. 16-ene-26,27-bishomo cholecalciferols
EP0808833A2 (fr) * 1996-05-23 1997-11-26 F. Hoffmann-La Roche Ag Analogues de la vitamine D3
US5872113A (en) * 1997-05-16 1999-02-16 Syntex (U.S.A.) Inc. Fluorinated vitamin D3 analogs
US6479538B1 (en) * 1997-05-16 2002-11-12 Women And Infants Hospital Cyclic ether vitamin D3 compounds, 1α(OH)3-EPI-vitamin D3 compounds and uses thereof
EP1048661A2 (fr) * 1999-04-26 2000-11-02 F. Hoffmann-La Roche Ag Procédé de préparation d'un agent anti-ostéoporotique

Also Published As

Publication number Publication date
CH698144B1 (fr) 2009-05-29
BE1016292A3 (nl) 2006-07-04
JP2009035559A (ja) 2009-02-19
EA200401100A1 (ru) 2005-04-28
WO2005027923A1 (fr) 2005-03-31
NL1027109A1 (nl) 2005-03-29
JP2007506699A (ja) 2007-03-22
FR2859910B1 (fr) 2006-04-28
HK1085373A1 (en) 2006-08-25
CN100488511C (zh) 2009-05-20
EP1673096A1 (fr) 2006-06-28
NZ535531A (en) 2006-03-31
NL1027109C2 (nl) 2005-05-03
FR2859910A1 (fr) 2005-03-25
CN1615891A (zh) 2005-05-18
BRPI0404050A (pt) 2005-06-14

Similar Documents

Publication Publication Date Title
US10245240B2 (en) Treatment of prostate carcinoma
Numan et al. Medial preoptic area and onset of maternal behavior in the rat.
US20060035867A1 (en) Methods of treating cancer and the pain associated therewith using endothelin antagonists
US20080207769A1 (en) Method for treating benign prostatic hyperplasia
Schneider et al. Persistent testicular delta5-isomerase-3beta-hydroxysteroid dehydrogenase (delta5-3beta-HSD) deficiency in the delta5-3beta-HSD form of congenital adrenal hyperplasia.
Gunson et al. Prevention of spontaneous tumours in female rats by fadrozole hydrochloride, an aromatase inhibitor
KR20220045198A (ko) 에스트로겐-의존성 장애의 치료를 위한 gnrh 길항제
JP2009035559A (ja) 良性前立腺肥大の治療のためのビタミンｄ３アナログの使用
WO1998025623A1 (fr) Procedes et compositions destines a prevenir et a traiter la perte osseuse
Roylance et al. Current treatment of BPH
Moszczyńska et al. Precocious puberty and other endocrine disorders during mitotane treatment for paediatric adrenocortical carcinoma–case series and literature review
US11986507B1 (en) Micronutrient composition to improve men's health
Yapura Development of a non-steroidal aromatase inhibitor-based protocol for the control of ovarian function using a bovine model
WO2022115581A1 (fr) Méthodes de traitement de l'infertilité et/ou de l'endométriose comprenant ex-527
Utsumi et al. Effect of estrogen on receptor positive human esophageal carcinoma
Lau et al. Effects of Colprone® on in vitro release of androgens from the reproductive organs of the male rat
Schenkman et al. Hormonal Influences on Nephrolithiasis
Kohram Effect of Follicular Synchronization and Hormonal Alterations on Superstimulatory Response and Embryo Production in Cattle
CN101352446A (zh) 化合物及其在治疗良性前列腺增生及相关症状中的应用

Legal Events

Date Code Title Description
MM4A Lapse of a eurasian patent due to non-payment of renewal fees within the time limit in the following designated state(s)

Designated state(s): AM AZ BY KZ KG MD TJ TM RU